During her PhD research Willeke Ros studied the efficacy and safety of several of those medicines in the first patients. She also investigated whether the already registered immunotherapy pembrolizumab could be effective against rare tumors. On Wednesday September 18thshe will defend her thesis at Utrecht University.
Thesis defense Willeke Ros
17-09-2019
While some immunotherapies already help cancer patients, many more of this type of drugs that are aimed at encouraging the immune system to fight cancer are being developed.
Practical information about the defense can be found on Utrecht University's website.